Biohaven

Biohaven Capital Expenditures

The Capital Expenditures (CapEx) of Biohaven (BHVN) as of Oct 22, 2026 is -715,000.00 USD. In the previous year, Capital Expenditures (CapEx) was -4.05 M USD — a change of -82.34% (higher).

Capital Expenditures

-715,000.00USD

YoY

-82.34%

Last updated:

Capital Expenditures (CapEx) of Biohaven is 2025 -715,000.00 USD. Capital Expenditures (CapEx) of Biohaven was 2024 -4.05 M USD. It decreases by -82.34% higher compared to the previous year.

The Biohaven Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-4.17 M USD
Jan 1, 2019
-2.53 M USD
Jan 1, 2020
-2.70 M USD
Jan 1, 2021
-938,000.00 USD
Jan 1, 2022
-41.07 M USD
Jan 1, 2023
-3.05 M USD
Jan 1, 2024
-4.05 M USD
Jan 1, 2025
-715,000.00 USD
The Biohaven Capital Expenditures history
YEARCapital ExpendituresYoY
-715,000.00USD-82.34%
-4.05 MUSD+32.84%
-3.05 MUSD-92.58%
-41.07 MUSD+4,278.89%
-938,000.00USD-65.22%
-2.70 MUSD+6.43%
-2.53 MUSD-39.16%
-4.17 MUSD+669.87%
-541,000.00USD+1,703.33%
-30,000.00USD—
0.00USD-100.00%
-10,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

Capital Expenditures (CapEx) of Biohaven is -715,000.00 USD in 2025.

Capital Expenditures (CapEx) of Biohaven changed from -4.05 M USD to -715,000.00 USD, representing a -82.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Biohaven since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Biohaven historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biohaven

All Key Metrics — Biohaven